Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 15, 2025
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction TreatmentRemo Panaccione, Gil Y Melmed, David Drobne, et al.Pharmaceutics|October 23, 2021
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic ModelJurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 29, 2020
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical RemissionJurij Hanžel, Jurij Zdovc, Tina Kurent, et al.Cells|January 8, 2025
Assessment of Extracellular Particles Directly in Diluted Plasma and Blood by Interferometric Light Microscopy. A Study of 613 Human and 163 Canine SamplesBoštjan Korenjak, Armando Tratenšek, Matevž Arko, et al.Journal of Crohn'S & Colitis|February 23, 2023
Non-hepatic Solid Organ Transplant in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case SeriesDavide Giuseppe Ribaldone, Sophie Vieujean, Mette Julsgaard, et al.Therapeutic Advances in Gastroenterology|May 17, 2021
Effect of COVID-19 pandemic on the workflow of endoscopy units: an international surveyTamás Resál, Renáta Bor, Kata Szántó, et al.BMC Proceedings|December 9, 2021
Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert's and patient's perspectiveLaimas Jonaitis, Srdjan Marković, Klaudia Farkas, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2014
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's diseaseDavid Drobne, Peter Bossuyt, Christine Breynaert, et al.Scandinavian Journal of Gastroenterology|July 11, 2018
Success and safety of high infliximab trough levels in inflammatory bowel diseaseDavid Drobne, Tina Kurent, Sasa Golob, et al.Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.Pageof 5